Exelixis reported $390.27M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bayer EUR 9.92B 121M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
Eisai JPY 218.93B 9.33B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 390.27M 10M Sep/2026
Genmab DKK 748M 77M Jun/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
MacroGenics USD 25.15M 17.72M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sanofi EUR 9.92B 941M Jun/2026
Takeda JPY 981.78B 36.71B Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026